BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, at 1:30 p.m. PT (4:30 p.m. ET).

Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the presentation of preclinical data of its lead investigational therapies: XTX201, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4 antibody

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its software-as-a-service division is expanding its solutions portfolio into new markets to provide data interoperability and accounts receivable optimization to the healthcare industry.

Advent Technologies, an innovation-driven company in the fuel cell and hydrogen technology space, today announced the appointment of Katherine E. Fleming as a new Member of its Board of Directors, in the context of its planned merger with AMCI Acquisition Corp (NASDAQ: AMCI) and the upcoming Nasdaq listing. Advent has recently announced a definitive agreement to merge with AMCI Acquisition

ENDRA Life Sciences Inc. today announced that Rocky Vista University College of Osteopathic Medicine (“RVUCOM”) has begun scanning patients in its clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the formation of a partnership with Baylor College of Medicine in Houston, Texas to act as the lead clinical site for the Company’s upcoming Phase III clinical trial.

PainReform Ltd. welcomes Dr. Ellen Baron as a member of the Company’s Board of Directors following its recent initial public offering.

Discovery Life Sciences™, a global leader in biospecimen solutions, genomic, cell, and immunohistochemistry services, announces the addition of Illumina’s TruSight Oncology 500 technology to HudsonAlpha Discovery, Discovery’s highly recognized and regarded sequencing and bioinformatics laboratory.

InMed Pharmaceuticals Inc. Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM”

Selva Therapeutics, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Selva also announced preclinical data demonstrating in several host cell